STOCK TITAN
  1. Home
  2. Sec-filings
  3. BCAX
  4. [Form 4] Bicara Therapeutics Inc. Insider Trading Activity

[Form 4] Bicara Therapeutics Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bicara Therapeutics Chief Financial Officer Hyep Ivan exercised stock options and sold the resulting shares in a coordinated transaction. On April 21, 2026, he exercised options to acquire 9,200 shares of common stock at $3.7898 per share, then sold 9,200 shares in open-market trades at a weighted-average price of $23.0015 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2025. After the transactions, he directly owned 145,355 common shares and had 39,744 stock options remaining, with the option award scheduled to vest in sixteen equal quarterly installments following April 5, 2023 and expiring on April 5, 2033.

Positive

  • None.

Negative

  • None.
Insider Hyep Ivan
Role Chief Financial Officer
Sold 9,200 shs ($212K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 9,200 $0.00 --
Exercise Common Stock 9,200 $3.7898 $35K
Sale Common Stock 9,200 $23.0015 $212K
Holdings After Transaction: Stock Option (Right to Buy) — 39,744 shares (Direct, null); Common Stock — 154,555 shares (Direct, null)
Footnotes (1)
  1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.68 to $23.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
Shares sold 9,200 shares Open-market sale of common stock on April 21, 2026
Sale price (weighted average) $23.0015 per share Common stock sale prices ranged from $22.68 to $23.50
Option exercise price $3.7898 per share Exercise price for 9,200 stock options converted to common stock
Shares held after transaction 145,355 shares Direct common stock ownership following April 21, 2026 transactions
Options exercised 9,200 options Stock Option (Right to Buy) converted to common stock on April 21, 2026
Remaining stock options 39,744 options Stock options outstanding after the reported exercise
Option expiration date April 5, 2033 Expiration of the Stock Option (Right to Buy) grant
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vesting in sixteen equal quarterly installments financial
"The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hyep Ivan
(Last)(First)(Middle)
BICARA THERAPEUTICS INC.
116 HUNTINGTON AVENUE, SUITE 703
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/21/2026M(1)9,200A$3.7898154,555D
Common Stock04/21/2026S(1)9,200D$23.0015(2)145,355D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$3.789804/21/2026M(1)9,200 (3)04/05/2033Common Stock9,200$039,744D
Explanation of Responses:
1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.68 to $23.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
Remarks:
/s/ Lara Meisner, Attorney-in-Fact04/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Bicara Therapeutics (BCAX) report for its CFO?

Bicara Therapeutics reported that CFO Hyep Ivan exercised stock options for 9,200 shares and sold 9,200 common shares in open-market trades on April 21, 2026, reflecting a typical exercise-and-sell liquidity transaction.

At what prices did the Bicara Therapeutics (BCAX) CFO exercise and sell shares?

The CFO exercised stock options at $3.7898 per share and sold 9,200 common shares at a weighted-average price of $23.0015 per share, with individual sale prices ranging from $22.68 to $23.50, according to the filing footnotes.

How many Bicara Therapeutics (BCAX) shares does the CFO hold after the Form 4 transaction?

Following the reported transactions, CFO Hyep Ivan directly held 145,355 shares of Bicara Therapeutics common stock. The filing also shows he retained 39,744 stock options after exercising part of an existing option grant linked to his compensation.

Was the Bicara Therapeutics (BCAX) CFO sale made under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state the sale was executed under a Rule 10b5-1 trading plan adopted on February 13, 2025. Such pre-arranged plans automate trades, indicating the timing was set in advance rather than decided opportunistically.

What stock option terms apply to the Bicara Therapeutics (BCAX) CFO’s remaining options?

The remaining stock options relate to an award that vests in sixteen equal quarterly installments after April 5, 2023, subject to continued service, and carry an exercise price of $3.7898 per share with an expiration date of April 5, 2033.

Does the Bicara Therapeutics (BCAX) Form 4 indicate a net share sale by the CFO?

The transaction summary shows 9,200 shares sold and an exercise of options for 9,200 shares, resulting in a small net-sell position overall. However, he still holds a substantial remaining stake in Bicara Therapeutics common shares and options.